GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nanjing Pharmaceutical Group Co 600713.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

5.25

-1.32%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥54.96bn

FY2016FY2025

Net income

CN¥624.8m

FY2016FY2025

Free cash flow

−CN¥159.6m

FY2016FY2025

Shareholders' equity

CN¥7.19bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥54.96bnCN¥53.70bnCN¥53.59bnCN¥50.22bnCN¥45.12bnCN¥39.82bnCN¥37.16bnCN¥31.30bnCN¥28.81bnCN¥26.72bn
Gross profitCN¥3.38bnCN¥3.35bnCN¥3.31bnCN¥3.25bnCN¥2.93bnCN¥2.52bnCN¥2.46bnCN¥2.07bnCN¥1.85bnCN¥1.57bn
Research and developmentCN¥46.8mCN¥30.6mCN¥36.2mCN¥27.4mCN¥21.0mCN¥16.0mCN¥13.4mCN¥10.9mCN¥1.7mCN¥1.7m
Operating incomeCN¥1.53bnCN¥1.02bnCN¥1.51bnCN¥934.3mCN¥845.7mCN¥1.04bnCN¥968.7mCN¥479.7mCN¥425.2mCN¥347.0m
Net incomeCN¥624.8mCN¥570.6mCN¥577.8mCN¥595.7mCN¥505.2mCN¥376.4mCN¥346.9mCN¥264.3mCN¥232.4mCN¥180.3m
Diluted earnings per share0.440.430.440.460.500.370.330.260.260.20

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥31.43bnCN¥30.67bnCN¥28.41bnCN¥31.65bnCN¥25.89bnCN¥23.41bnCN¥21.97bnCN¥19.55bnCN¥15.93bnCN¥13.96bn
Cash and short-term investments—CN¥4.56bnCN¥2.37bnCN¥2.33bnCN¥2.09bnCN¥1.48bnCN¥2.10bnCN¥2.27bnCN¥1.85bnCN¥1.21bn
Total liabilitiesCN¥23.18bnCN¥22.89bnCN¥21.16bnCN¥24.96bnCN¥20.65bnCN¥18.59bnCN¥17.45bnCN¥15.45bnCN¥12.74bnCN¥10.89bn
DebtCN¥4.15bnCN¥7.50bnCN¥11.62bnCN¥5.61bnCN¥6.50bnCN¥6.32bnCN¥3.16bnCN¥3.10bnCN¥5.23bnCN¥1.77bn
Shareholders' equityCN¥7.19bnCN¥6.84bnCN¥6.44bnCN¥6.00bnCN¥4.61bnCN¥4.26bnCN¥4.01bnCN¥3.67bnCN¥2.78bnCN¥2.63bn
Shares outstanding1,409m1,312m1,309m1,304m1,018m1,030m1,047m1,036m891m888m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥91.8mCN¥2.14bnCN¥1.91bn−CN¥682.3mCN¥695.3m−CN¥1.15bnCN¥1.00bn−CN¥366.9mCN¥320.0m−CN¥240.9m
Capital spending−CN¥251.4m−CN¥544.8m−CN¥158.2m−CN¥155.3m−CN¥306.5m−CN¥247.0m−CN¥300.7m−CN¥311.5m−CN¥240.6m−CN¥195.8m
Free cash flow−CN¥159.6mCN¥1.59bnCN¥1.75bn−CN¥837.6mCN¥388.8m−CN¥1.40bnCN¥703.2m−CN¥678.4mCN¥79.4m−CN¥436.7m
Dividends paid−CN¥492.6m−CN¥504.8m−CN¥587.9m−CN¥482.9m−CN¥934.9m−CN¥352.8m−CN¥500.9m−CN¥368.9m−CN¥368.5m−CN¥146.4m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥13.98bnCN¥13.84bnCN¥13.83bnCN¥13.17bnCN¥13.72bnCN¥14.25bnCN¥12.76bnCN¥13.71bn
Gross profitCN¥807.8mCN¥869.4mCN¥935.2mCN¥796.7mCN¥801.1mCN¥849.3mCN¥831.2mCN¥849.3m
Operating incomeCN¥369.2mCN¥454.3mCN¥379.7mCN¥183.2mCN¥326.0mCN¥393.1mCN¥251.8mCN¥226.1m
Net incomeCN¥119.9mCN¥174.6mCN¥222.9mCN¥110.7mCN¥113.9mCN¥177.4mCN¥128.7mCN¥130.6m
Diluted earnings per share0.090.120.160.080.080.130.100.10
Cash from operations———−CN¥942.0m−CN¥431.0m−CN¥3.60bnCN¥5.03bn−CN¥541.0m
Capital spending−CN¥39.0m−CN¥69.0m−CN¥74.0m−CN¥36.0m−CN¥72.0m−CN¥67.0m−CN¥66.0m−CN¥110.0m
Free cash flow———−CN¥978.0m−CN¥503.0m−CN¥3.67bnCN¥4.96bn−CN¥651.0m
Total assetsCN¥36.33bnCN¥35.50bnCN¥31.43bnCN¥34.05bnCN¥33.21bnCN¥33.48bnCN¥30.67bnCN¥32.45bn
Cash and short-term investments———CN¥1.98bnCN¥2.39bnCN¥2.65bnCN¥4.56bnCN¥1.16bn
DebtCN¥4.64bnCN¥4.11bnCN¥4.15bnCN¥6.61bnCN¥7.95bnCN¥9.79bnCN¥7.38bnCN¥12.14bn
Shareholders' equityCN¥7.25bnCN¥7.36bnCN¥7.19bnCN¥6.97bnCN¥6.86bnCN¥7.02bnCN¥6.84bnCN¥6.71bn

Financial ratios

Data as of 11 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin6.2%6.2%6.2%6.5%6.5%6.3%
Operating margin2.7%2.9%2.8%2.7%2.9%2.6%
Net margin1.1%1.1%1.1%1.2%1.1%0.9%
Return on equity8.7%8.3%9.0%9.9%11.0%8.8%
Return on assets2.0%1.9%2.0%1.9%2.0%1.6%
Free cash flow yield4.7%39.7%30.7%-7.9%19.1%-17.1%
Revenue growth2.4%0.2%6.7%11.3%13.3%7.2%
Earnings growth9.5%-1.2%-3.0%17.9%34.2%8.5%
Current ratio1.53x1.63x1.40x1.31x1.34x1.23x
Debt to equity0.58x1.08x1.39x0.92x2.12x2.04x
Equity ratio22.9%22.3%22.7%19.0%17.8%18.2%
Interest coverage4.75x2.90x2.79x3.03x2.84x2.82x
R&D as a share of sales0.1%0.1%0.1%0.1%0.0%0.0%
Buybacks as a share of market value-7.3%-0.2%-0.4%-28.1%1.2%1.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue3.1%6.7%8.3%
Operating income18.0%8.2%19.5%
Net income1.6%10.7%14.8%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin6.2%6.3%6.3%6.3%
Operating margin2.4%2.4%2.3%2.1%
Net margin1.1%1.1%1.1%1.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings12.311.411.011.29.912.214.116.723.839.2
Price to sales0.10.10.10.10.10.10.10.10.20.3

Dividends and splits

Per share, in the currency the company pays

Paid for 10 years. Last went ex-dividend on 17 Sept 2026.

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Paid in the year0.260.170.160.140.120.110.100.10
  • 2-for-1 split · 8 Jul 2011
  • 6-for-5 split · 10 Jun 2009
  • 1.291-for-1 split · 17 Jul 2006
  • 9-for-5 split · 30 Apr 1998

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.